Versatility of gene therapy vectors through viruses

Bibliography

• THOMAS CE, EHRHARDT A, KAY MA: Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. (2003) 4:346–358.
   PubMed Web of Science ®Google Scholar
• BARZON L, BOSCARO M, PALU G: Endocrine aspects of cancer gene therapy. Endocr. Rev. (2004) 25:1–44.
   PubMed Web of Science ®Google Scholar
• RUSSELL WC: Update on adenovirus and its vectors. J. Gen. Virol (2000) 81:2573–2604.
   PubMed Web of Science ®Google Scholar
• MIZUGUCHI H, KAY MA, HAYAKAWA T: Approaches for generating recombinant adenovirus vectors. Adv. Drug Deliv. Rev. (2001) 52:165–176.
   PubMed Web of Science ®Google Scholar
• MARSHALL E: Clinical trials: gene therapy death prompts review of adenovirus vector. Science (1999) 286:2244–2245.
   PubMed Web of Science ®Google Scholar
• RAPER SE, YUDKOFF M, CHIRMULE N et al.: A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum. Gene Ther. (2002) 13:163–175.
   PubMed Web of Science ®Google Scholar
• NIH REPORT: Assessment of adenoviral vector safety and toxicity: Report of the National Institutes of Health of Recombinant DNA Advisory Committee. Hum. Gene Ther. (2002) 13:3–13.
   PubMed Web of Science ®Google Scholar
• •After the death of a patient due to adenoviral vector toxicity, the RAC reports studies on the side-effects of adenoviral vectors.
   Google Scholar
• ST GEORGE JA: Gene therapy progress and prospects: adenoviral vectors. Gene Ther. (2003) 10:1135–1141.
   PubMed Web of Science ®Google Scholar
• SCHNELL MA, ZHANG Y, TAZELAAR J et al.: Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol. Ther. (2001) 3:708–722.
   PubMed Web of Science ®Google Scholar
• MORRAL N, O& NEAL WK, RICE K et ed.:Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum. Gene Ther. (2002) 13:143–154.
   Google Scholar
• HIGGINBOTHAM JN, SETH P, BLAESE RM, RAMSEY WJ: The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid. Hum. Gene Ther. (2002) 13:129–141.
   PubMed Web of Science ®Google Scholar
• DE GEEST B, VAN LINTHOUT S, LOX M, COLLEN D, HOLVOET P: Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer. Hum. Gene Ther. (2000) 11:101–112.
   PubMed Web of Science ®Google Scholar
• GERDES CA, CASTRO MG, LOWENSTEIN PR: Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo. Mol. Ther. (2000) 2:330–338.
   PubMed Web of Science ®Google Scholar
• JI L, BOUVET M, PRICE RE, ROTH JA, FANG B: Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted El -E3 and inactivated E4 by GAL4-TATA promoter replacement. Gene Ther. (1999) 6:393–402.
   PubMed Web of Science ®Google Scholar
• CHRIST M, LOUIS B, STOECKEL F et al.: Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products. Hum. Gene Ther. (2000) 11:415–427.
   PubMed Web of Science ®Google Scholar
• EVERETT RS, HODGES BL, DING EY, XU F, SERRA D, AMALFITANO A: Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of El, E2b-deleted adenoviral vectors. Hum. Gene Ther. (2003) 14:1715–1726.
   PubMed Web of Science ®Google Scholar
• O'NEAL WK, ZHOU H, MORRAL N et al.: Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. Mol. Med. (2000) 6:179–195.
   Google Scholar
• AMALFITANO A: Use of multiply deletedadenovirus vectors to probe adenovirus vector performance and toxicities. Curr. Opin. Mol. Ther. (2003) 5:362–366.
   PubMed Web of Science ®Google Scholar
• MURUVE DA, COTTER MJ, ZAISS AK et al.: Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J. Virol. (2004) 78:5966–5972.
   PubMed Web of Science ®Google Scholar
• EFSTATHIOU S, KEMP S, DARBY G, MINSON AC: The role of herpes simplex virus type 1 thymidine kinase in pathogenesis. J. Gen. Virol (1989) 70:869–879.
   PubMed Web of Science ®Google Scholar
• JACOBSON JG, LEIB DA, GOLDSTEIN DJ et al.: A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology (1989) 173:276–283.
   PubMed Web of Science ®Google Scholar
• CHOU J, KERN ER, -WHITLEY RJ, ROIZMAN B: Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science (1990) 250:1262–1266.
   Google Scholar
• POST DE, FULCI G, CHIOCCA EA, VAN MEIR EG: Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr. Gene Ther. (2004) 4:41–51.
   PubMed Web of Science ®Google Scholar
• PRESTON CM, MABBS R, NICHOLL MJ: Construction and characterization of herpes simplex virus type 1 mutants with conditional defects in immediate early gene expression. Virology (1997) 229:228–239.
   PubMed Web of Science ®Google Scholar
• SAMANIEGO LA, NEIDERHISER L, DELUCA NA: Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J. ViroL (1998) 72:3307–3320.
   PubMed Web of Science ®Google Scholar
• •Design and evaluation of non-replicative genomic HSV vectors.
   Google Scholar
• LUNDSTROM K: Alphavirus vectors forgene therapy applications. Curr. Gene Ther. (2001) 1:19–29.
   PubMedGoogle Scholar
• TUITTILA MT, SANTAGATI MG, ROYTTA M, MAATTA JA, HINKKANEN AE: Replicase complex genes of Semliki Forest virus confer lethal neurovirulence. j ViroL (2000) 74:4579–4589.
   PubMed Web of Science ®Google Scholar
• YANG Y, LI Q, ERTL HC, WILSON JM: Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. j Wrol. (1995) 69:2004–2115.
   Google Scholar
• YANG Y, WILSON JM: Clearance of adenovirus-infected hepatocytes by class-I restricted CD4+ CTLs in vivo. J. ImmunoL (1995) 155:2564–2570.
   PubMed Web of Science ®Google Scholar
• WOLD WS, GOODING LR: Region E3 of adenovirus: a cassette of genes involved in host immunosurveillance and virus-cell interactions. Virology (1991) 184:1–8.
   PubMedGoogle Scholar
• LUSKY M, CHRIST M, PITTNER K et al.: In vitro and in vivo biology of recombinant adenovirus vectors with El, El/E2A, or El/E4 deleted. J. ViroL (1998) 72:2022–2032.
   PubMed Web of Science ®Google Scholar
• GORZIGLIA MI, KADAN MJ, YEI S et aL: Elimination of both El and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J. ViroL (1996) 70:4173–8.
   PubMed Web of Science ®Google Scholar
• MORRAL N, O& NEAL W, RICE K et al.:Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc. Natl. Acad. Sci. USA (1999) 96:12816–12821.
   Google Scholar
• MORSY MA, CASKEY CT: Expanded-capcity adenoviral vectors-the helper-dependent vectors. MoL Med. Thday (1999) 5:18–24.
   PubMedGoogle Scholar
• LOSER P, HILLGENBERG M, ARNOLD W, BOTH GW, HOFMANN C: Ovine adenovirus vectors mediate efficient gene transfer to skeletal muscle. Gene Ther. (2000) 7:1491–1498.
   PubMed Web of Science ®Google Scholar
• PARKS R, EVELEGH C, GRAHAM F: Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther. (1999) 6:1565–1573.
   PubMed Web of Science ®Google Scholar
• CROYLE MA, LE HT, LINSE KD et aL:PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther. (2005) 12:579–587.
   PubMed Web of Science ®Google Scholar
• FISHER KD, STALLWOOD Y, GREEN NK, ULBRICH K, MAUTNER V, SEYMOUR LW: Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. (2001) 8:341–348.
   PubMed Web of Science ®Google Scholar
• YOTNDA P, CHEN DH, CHIU W et al.: Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mo/. Ther. (2002) 5:233–241.
   PubMed Web of Science ®Google Scholar
• BROCKMAN MA, KNIPE DM: Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity. J. ViroL (2002) 76:3678–3687.
   PubMed Web of Science ®Google Scholar
• LAMBRIGHT ES, KANG EH, FORCE S et aL: Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model. MoL Ther. (2000) 2:387–393.
   PubMed Web of Science ®Google Scholar
• DUAN D, SHARMA P, DUDUS Let aL:Formation of adeno-associated virus circular genomes is differentially regulated by adenovirus E4 ORF6 and E2a gene expression. J. ViroL (1999) 73:161–169.
   PubMed Web of Science ®Google Scholar
• SANLIOGLU S, DUAN D, ENGELHARDT JF: Two independent molecular pathways for recombinant adeno-associated virus genome conversion occur after UV-C and E4orf6 augmentation of transduction. Hum. Gene Ther. (1999) 10:591–602.
   PubMed Web of Science ®Google Scholar
• KOTIN RM, LINDEN RM, BERNS KI: Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J. (1992) 11:5071–5078.
   PubMed Web of Science ®Google Scholar
• KEARNS WG, AFIONE SA, FULMER SB et aL: Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line. Gene Ther. (1996) 3:748–755.
   PubMed Web of Science ®Google Scholar
• ERLES K, SEBOKOVA P, SCHLEHOFER JR: Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J. Med. ViroL (1999) 59:406–411.
   PubMed Web of Science ®Google Scholar
• GRIMM D, KAY MA, KLEINSCHMIDT JA: Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. MoL Ther. (2003) 7:839–850.
   PubMed Web of Science ®Google Scholar
• HALBERT CL, RUTLEDGE EA, ALLEN JM, RUSSELL DW, MILLER AD: Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. j Virol. (2000) 74:1524–1532.
   PubMed Web of Science ®Google Scholar
• RABINOWITZ JE, ROLLING F, LI C: Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. ViroL (2002) 76:791–801.
   Web of Science ®Google Scholar
• MCLAUGHLIN SK, COLLIS P, HERMONAT PL, MUZYCZKA N: Adeno-associated virus general transduction vectors: analysis of proviral structures. ViroL (1988) 62:1963–1973.
   Web of Science ®Google Scholar
• VANIN EF, KALOSS M, BROSCIUS C, NIENHUIS AW: Characterization of replication-competent retroviruses from nonhuman primates with virus-induced T-cell lymphomas and observations regarding the mechanism of oncogenesis. ViroL (1994) 68:4241–4250.
   Web of Science ®Google Scholar
• KOCHANEK S, SCHIEDNER G, VOLPERS C: High-capacity 'gutless' adenoviral vectors. Curr. Opin. Mol. Ther. (2001) 3:454–463.
   PubMed Web of Science ®Google Scholar
• HARDY S, KITAMURA M, HARRIS-STANSIL T, DAI Y, PHIPPS ML: Construction of adenovirus vectors through Cre-lox recombination.ViroL (1997) 71:1842–1849.
   Google Scholar
• CHESHENKO N, KROUGLIAK N, EISENSMITH RC, KROUGLIAK VA: A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus. Gene Ther. (2001) 8:846–854.
   PubMed Web of Science ®Google Scholar
• SAKHUJA K, REDDY PS, GANESH S et aL: Optimization of the generation and propagation of gutless adenoviral vectors. Hum. Gene Ther. (2003) 14:243–254.
   PubMed Web of Science ®Google Scholar
• SPAETE R, FRENKEL N: The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning amplifying vector. Cell (1982) 30:295–304.
   PubMed Web of Science ®Google Scholar
• ••Report on the HSV amplicon vector.
   Google Scholar
• GELLER AT, KEYOMARSI K, BRYAN J, PARDEE AB: An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology. Proc. Natl Acad. Sci. USA (1990) 87:8950–8954.
   PubMed Web of Science ®Google Scholar
• LIM F, HARTLEY D, STARR P et al.: Generation of high-titre defective HSV-1 vectors using an IE 2 deletion mutant and quantitative study of expression in cultured cortical cells. Bio Techniques (1996) 20:460–469.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM C, DAVISON AJ: A cosmid-based system for constructing mutants of herpes simplex virus type 1. Virology (1993) 197:116–124.
   PubMed Web of Science ®Google Scholar
• FRAEFEL C, SONG S, LIM F et al.: Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J. Virol (1996) 70:7190–7197.
   PubMed Web of Science ®Google Scholar
• SAEKI Y, ICHIKAWA T, SAEKI A et ell.: Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum. Gene Ther. (1998) 9:2787–2794.
   Google Scholar
• STAVROPOULOS TA, STRATHDEE CA: An enhanced packaging system for helper-dependent herpes simplex virus vectors. J. Wrol. (1998) 72:7137–7143.
   Google Scholar
• KRISKY DM, MARCONI PC, OLIGINO TJ et al: Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Ther. (1998) 5:1517–1530.
   PubMed Web of Science ®Google Scholar
• LILLEY CE, GROUTSI F, HAN Z et al:Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo. J. Virol (2001) 75:4343–4356.
   PubMed Web of Science ®Google Scholar
• HERMONAT PL, MUZYCZKAN: Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc. Nail. Acad. Sci. USA (1984) 81:6466–6470.
   PubMed Web of Science ®Google Scholar
• HAUSWIRTH WW, LEWIN AS, ZOLUTUKHIN S, MUZYCZKA N: Production and purification of recombinant adeno-associated virus. Methods Enzymol (2000) 316:743–761.
   PubMed Web of Science ®Google Scholar
• CLARK KR, VOULGAROPOULOU F, FRALEY DM, JOHNSON PR: Cell lines for the production of recombinant adeno-associated virus. Hum. Gene Ther. (1995) 6:1329–1341.
   PubMed Web of Science ®Google Scholar
• MATSUSHITA T, ELLIGER S, ELLIGER C et al.: Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. (1998) 5:938–945.
   PubMed Web of Science ®Google Scholar
• XIAO X, LI J, SAMULSKI RJ: Production of high-titre recombinant adeno-associated virus vectors in the absence of helper adenovirus. j Wrol. (1998) 72:2224–2232.
   Google Scholar
• SALVETTI A. OREVE S, CHADEUF G et al.: Factors influencing recombinant adeno-associated virus production. Hum. Gene Ther. (1998) 9:695–706.
   Google Scholar
• GRIMM D, KERN A. RITTNER K, KLEINSCHMIDT JA: Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum. Gene Ther. (1998) 9:2745–2760.
   PubMed Web of Science ®Google Scholar
• PALU G, PAROLIN C, TAKEUCHI Y, PIZZATO M: Progress with retroviral gene vectors. Rev. Med. Virol (2000) 10:185–202.
   PubMed Web of Science ®Google Scholar
• PAGES JC, BRU T: Toolbox for retrovectorologists. J. Gene Med. (2004) 6:S67–S82.
   PubMed Web of Science ®Google Scholar
• MUENCHAU DD, FREEMAN SM, CORNETTA K, ZWIEBEL JA, ANDERSON WF: Analysis of retroviral packaging lines for generation of replication-competent virus. Virology (1990) 176:262–265.
   PubMed Web of Science ®Google Scholar
• CHONG H, STARKEY W, VILE RG: A replication-competent retrovirus arising from a split-function packaging cell line was generated by recombination events between the vector, one of the packaging constructs and endogenous retroviral sequences. J. Virol (1994) 72:2663–2670.
   Google Scholar
• RONFORT C, GIROD A, COSSET FL: Defective retroviral endogenous RNA is efficiently transmitted by infectious particles produced on an avian retroviral vector packaging cell line. Virology (1995) 207:271–275.
   PubMed Web of Science ®Google Scholar
• NALDINI L, BLOMER U, GALLAY P et al.: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 272:263–267.
   PubMed Web of Science ®Google Scholar
• •First characterisation of lentiviral vectors.
   Google Scholar
• ZUFFEREY R, NAGY D, MANDEL RJ, NALDINI L, TRONO D: Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol (1997) 15:871–875.
   PubMed Web of Science ®Google Scholar
• DULL T, ZUFFEREY R, KELLY M et al: A third-generation lentivirus vector with a conditional packaging system. J. Wrol. (1998) 72:8463–8471.
   Google Scholar
• ••Development of third-generationlentiviral vectors.
   Google Scholar
• ZUFFEREY R, DULL T, MANDEL RJ et al: Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. Wrol. (1998) 72:9873–9880.
   Google Scholar
• MIYOSHI H, BLOMER U, TAKAHASHI, M, GAGE FH, VERMA IM: Development of a self-inactivating lentivirus vector. J. Wrol. (1998) 72:8150–8157.
   Google Scholar
• BUKOVSKY AA, SONG JP, NALDINI L:Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J. Virol (1999) 73:7087–7092.
   PubMed Web of Science ®Google Scholar
• LOGAN AC, HAAS DL, KAFRI T, KOHN DB: Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration. J. Virol (2004) 78:8421–8436.
   PubMed Web of Science ®Google Scholar
• •Self-inactivating lentiviral vectors may still produce genomic transcripts.
   Google Scholar
• POESCHLA E, WONG-STAAL F, LOONEY D: Efficient transduction of nondividing cells by feline immunodeficiency virus lentiviral vectors. Nat. Med. (1998) 4:354–357.
   PubMed Web of Science ®Google Scholar
• SAENZ DT, POESCHLA EM: FIV: from lentivirus to lentivector. J. Gene Med. (2004) 6:595–5104.
   Google Scholar
• OLSEN JC: Gene transfer vectors derivedfrom equine infectious anemia virus. Gene Ther. (1998) 5:1481–1487.
   PubMed Web of Science ®Google Scholar
• O'ROURKE JP, NEWBOUND GC, KOHN DB, OLSEN JC, BUNNELL BA: Comparison of gene transfer efficiencies and gene expression levels achieved with equine infectious anemia virus- and human immunodeficiency virus type 1-derived lentivirus vectors. J. Wrol. (2002) 76:1510–1515.
   Google Scholar
• MAURY W: Regulation of equine infectious anemia virus expression. Biomed. Sci. (1998) 5:11–23.
   Google Scholar
• O'ROURKE JP, HIRARAGI H, URBAN K, PATEL M, OLSEN JC, BUNNELL BA: Analysis of gene transfer and expression in skeletal muscle using enhanced EIAV lentivirus vectors. Mol. Ther. (2003) 7(5 Pt 1):632–639.
   Google Scholar
• IMLER JL, CHARTIER C, DREYER D et al.: Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of El-deleted adenovirus vectors. Gene Ther. (1996) 3:75–84.
   PubMed Web of Science ®Google Scholar
• FALLAUX FJ, BOUT A, VAN DER VELDE let al.: New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. (1998) 9:1909–1917.
   Google Scholar
• XIE L, METALLO C, WARREN J et al.: Large-scale propagation of a replication-defective adenovirus vector in stirred-tank bioreactor PER.C6 cell culture under sparging conditions. Biotechnol Bioeng-. (2003) 83:45–52.
   Google Scholar
• MURAKAMI P, HAVENGA M, FAWAZ F et al.: Common structure of rare replication-deficient El-positive particles in adenoviral vector batches. J. ViroL (2004) 78:6200–6208.
   PubMed Web of Science ®Google Scholar
• KROUGLIAK V, GRAHAM FL: Development of cell lines capable of complementing El, E4, and protein IX defective adenovirus type 5 mutants. Hum. Gene Ther. (1995) 6:1575–1586.
   PubMed Web of Science ®Google Scholar
• PARKS RJ, CHEN L, ANTON M, SANKAR U, RUDNICKI MA, GRAHAM FL: A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Nail. Acad. Sci. USA (1996) 93:13565–13570.
   PubMed Web of Science ®Google Scholar
• GAO L, LIU Y, DURING MJ, XIAO W: High-titre, wild-type free recombinant adeno-associated virus vector production using intron-containing helper plasmids. J. Wrol. (2000) 74:11456–11463.
   Google Scholar
• WU X, LI Y, CRISE B, BURGESS SM: Transcription start regions in the human genome are favored targets for MLV integration. Science (2003) 300:1749–1751.
   PubMed Web of Science ®Google Scholar
• ••Characterisation of chromosomalintegration sites of MLV and HIV.
   Google Scholar
• BAUM C, DULLMANN J, LIZ et al.: Side effects of retroviral gene transfer into hematopoietic stem cells. Blood (2003) 101:2099–2114.
   PubMed Web of Science ®Google Scholar
• SADELAIN M: Insertional oncogenesis ingene therapy: how much of a risk? Gene Ther. (2004) 11:569–573.
   Google Scholar
• KIEM HP, SELLERS S, THOMASSON B et al.: Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: no progression to clonal hematopoiesis or leukemia. MoL Ther. (2004) 9:389–395.
   PubMed Web of Science ®Google Scholar
• KOHN DB, SADELAIN M, GLORIOSO JC: Occurrence of leukaemia following gene therapy of X-linked SCID. Nat. Rev. Cancer (2003) 3:477–488.
   PubMed Web of Science ®Google Scholar
• HACEIN-BEY-ABINA S, VON KALLE C, SCHMIDT M et al.: LM02-associated clonal T cell proliferation in two patients after gene therapy for SCID-Xl. Science (2003) 302:415–419.
   PubMed Web of Science ®Google Scholar
• DAVE UP, JENKINS NA, COPELAND NG: Gene therapy insertional mutagenesis insights. Science (2004) 303:333.
   PubMed Web of Science ®Google Scholar
• •The therapeutic gene contributed to the development of leukeamia due to insertional oncogenesis in the X-SCID gene therapy clinical trial.
   Google Scholar
• MCCORMACK MP, RABBITTS TH: Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl. J. Med. (2004) 350:913–922.
   PubMed Web of Science ®Google Scholar
• COUZIN J, KAISER J: Gene therapy. As Gelsinger case ends, gene therapy suffers another blow. Science (2005) 307:1028.
   Google Scholar
• KAISER J: Gene therapy. Panel urges limits on X-SCID trials. Science (2005) 307:1544–1545.
   Google Scholar
• SCHRODER AR., SHINN P, CHEN H, BERRY C, ECKER JR, BUSHMAN F: HIV-1 integration in the human genome favors active genes and local hotspots. Cell (2002) 110:521–529.
   PubMed Web of Science ®Google Scholar
• ••Characterisation of HIV integration sitesin the human genome.
   Google Scholar
• WOODS NB, MUESSIG A. SCHMIDT M et al.: Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis. Blood (2003) 101:1284–1289.
   Google Scholar
• LAUFS S, GENTNER B, NAGY KZ et al: Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells. Blood (2003) 101:2191–2198.
   PubMed Web of Science ®Google Scholar
• LAUFS S, NAGY KZ, GIORDANO FA, HOTZ-WAGENBLATT A, ZELLER WJ, FRUEHAUF S: Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns. MoL Ther. (2004) 10:874–881.
   PubMed Web of Science ®Google Scholar
• WI] X, BURGESS SM: Integration target site selection for retroviruses and transposable elements. Cell. MoL Lift Sci. (2004) 61:2588–2596.
   PubMed Web of Science ®Google Scholar
• YI Y, HAHM SH, LEE KH: Retroviral gene therapy: safety issues and possible solutions. Curr. Gene Ther. (2005) 5:25–35.
   PubMed Web of Science ®Google Scholar
• KRAUNUS J, SCHAUMANN DH, MEYER J et al.: Self-inactivating retroviral vectors with improved RNA processing. Gene Ther. (2004) 11:1568–1578.
   PubMed Web of Science ®Google Scholar
• RAMEZANI k HAWLEY TS, HAWLEY RG: Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator. Blood (2003) 101:4717–4724.
   PubMed Web of Science ®Google Scholar
• ••Combined use of insulators and SARs inretroviral vectors.
   Google Scholar
• GERASIMOVA TI, CORCES VG: Chromatin insulators and boundaries: effects on transcription and nuclear organization. Annu. Rev. Genet. (2001) 35:193–208.
   PubMedGoogle Scholar
• RIVELLA S, CALLEGARI JA, MAY C, TAN CW, SADELAIN M: The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J. ViroL (2000) 74:4679–4687.
   PubMed Web of Science ®Google Scholar
• •An insulator is used in retroviral vectors to prevent silencing of transgene expression.
   Google Scholar
• BURNS JC, FRIEDMANN T, DRIEVER W, BURRASCANO M, YEE JK: Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titre and efficient gene transfer into mammalian and nonmammalian cells. Proc. Nail Acad. Sci. USA (1993) 90:8033–8037.
   PubMed Web of Science ®Google Scholar
• LOEW R, SELEVSEK N, FEHSE B et al.: Simplified generation of high-titre retrovirus producer cells for clinically relevant retroviral vectors by reversible inclusion of a lox-P-flanked marker gene. Mo/. Ther. (2004) 9:738–746.
   PubMed Web of Science ®Google Scholar
• VERZELETTI S, BONINI C, MARKTEL S et al.: Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Hum. Gene Ther. (1998) 9:2243–2251.
   PubMed Web of Science ®Google Scholar
• LI Z, DULLMANN J, SCHIEDLMEIER B et al.: Murine leukemia induced by retroviral gene marking. Science (2002) 296:497.
   PubMed Web of Science ®Google Scholar
• LEE JT, YU SS, HAN E, KIM S, KIM S: Engineering the splice acceptor for improved gene expression and viral titre in an MLV-based retroviral vector. Gene Ther. (2004) 11:94–99.
   PubMed Web of Science ®Google Scholar
• DONELLO JE, LOEB JE, HOPE TJ: Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J. Virol. (1998) 72:5085–5092.
   PubMed Web of Science ®Google Scholar
• HLAVATY J, STRACKE A, KLEIN D, SALMONS B, GUNZBURG WH, RENNER M: Multiple modifications allow high-titre production of retroviral vectors carrying heterologous regulatory elements. Virol. (2004) 78:1384–1392.
   Web of Science ®Google Scholar
• WAHLFORS JJ, XANTHOPOULOS KG, MORGAN RA: Semliki Forest virus-mediated production of retroviral vector RNA in retroviral packaging cells. Hum. Gene Ther. (1997) 8:2031–2041.
   PubMed Web of Science ®Google Scholar
• KAMEN A, HENRY O: Development and optimization of an adenovirus production process. J. Gene Med. (2004) 6:S184–S192.
   PubMed Web of Science ®Google Scholar
• JARDON M, GARNIER A: pH, pCO2, and temperature effect on r-adenovirus production. Biotechnol Prog. (2003) 19:202–208.
   PubMed Web of Science ®Google Scholar
• OZUER A, WECHUCK JB, GOINS WF, WOLFE D, GLORIOSO JC, ATAAI MM: Effect of genetic background and culture conditions on the production of herpesvirus-based gene therapy vectors. Biotechnol Bioeng. (2002) 77:685–692.
   PubMed Web of Science ®Google Scholar
• WECHUCK JB, GOINS WF, GLORIOSO JC, ATAAI MM: Effect of protease inhibitors on yield of HSV-1-based viral vectors. Biotechnol. Prog. (2000) 16:493–496.
   PubMed Web of Science ®Google Scholar
• FERRARI FK, XIAO X, MCCARTY D, SAMULSKI RJ: New developments in the generation of Ad-free, high-titre rAAV gene therapy vectors. Nat. Med. (1997) 3:1295–1297.
   PubMed Web of Science ®Google Scholar
• FAN PD, DONG JY: Replication of rep-cap genes is essential for the high-efficiency production of recombinant AAV. Hum. Gene Ther. (1997) 8:87–98.
   PubMed Web of Science ®Google Scholar
• VINCENT KA, PIRAINO ST, WADSWORTH SC: Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products. J. Virol. (1997) 71:1897–1905.
   PubMed Web of Science ®Google Scholar
• LI J, SAMULSKI RJ, XIAO X: Role for highly regulated rep gene expression in adeno-associated virus vector production. J. Virol. (1997) 71:5236–5243.
   PubMed Web of Science ®Google Scholar
• INOUE N, RUSSELL DW: Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors. J. Virol. (1998) 72:7024–7031.
   PubMed Web of Science ®Google Scholar
• QIA0 C, WANG B, ZHU X, LI J, XIAO X: A novel gene expression control system and its use in stable, high-titre 293 cell-based adeno-associated virus packaging cell lines. J. Virol. (2002) 76:13015–13027.
   PubMed Web of Science ®Google Scholar
• QIA0 C, LI J, SKOLD A. ZHANG X, XIAO X: Feasibility of generating adeno-associated virus packaging cell lines containing inducible adenovirus helper genes. J. Virol. (2002) 76:1904–1913.
   Google Scholar
• CONWAY JE, RHYS CM, ZOLOTUKHIN I et al.: High-titre recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Gene Ther. (1999) 6:986–993.
   PubMed Web of Science ®Google Scholar
• SHIAU AL, LIU PS, WU CL: Novel strategy for generation and titration of recombinant adeno-associated virus vectors. J. Virol. (2005) 79:193–201.
   PubMed Web of Science ®Google Scholar
• HERMENS WT, TER BRAKE O, DIJKHUIZEN PA et al.: Purification of recombinant adeno-associated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system. Hum. Gene Ther. (1999) 10:1885–1891.
   PubMed Web of Science ®Google Scholar
• HILDINGER M, ABEL KI,, OSTERTAG W, BAUM C: Design of 5' untranslated sequences in retroviral vectors developed for medical use. J. Virol. (1999) 73:4083–4089.
   PubMed Web of Science ®Google Scholar
• SCHAMBACH A. WODRICH H, HILDINGER M, BOHNE J, KRAUSSLICH HG, BAUM C: Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Mol. Ther. (2000) 2:435–445.
   PubMed Web of Science ®Google Scholar
• FONG YW, ZHOU Q: Stimulatory effect of splicing factors on transcriptional elongation. Nature (2001) 414:929–933.
   PubMed Web of Science ®Google Scholar
• REED R, HURT E: A conserved mRNA export machinery coupled to pre-mRNA splicing. Cell (2002) 108:523–531.
   PubMed Web of Science ®Google Scholar
• HAMAGUCHI I, WOODS NB, PANAGOPOULOS I et al.: Lentivirus vector gene expression during ES cell-derived hematopoietic development in vitro. J. Virol. (2000) 74:10778–10784.
   PubMed Web of Science ®Google Scholar
• EMERMAN M, TEMIN HM: Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell (1984) 39:449–467.
   PubMedGoogle Scholar
• ZUFFEREY R, DONELLO JE, TRONO D, HOPE TJ: Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. (1999) 73:2886–2892.
   PubMed Web of Science ®Google Scholar
• ZENNOU V SERGUERA C, SARKIS C et al.: The HIV-1 DNA flap stimulates HIV vector-mediated cell transduction in the brain. Nat. Biotechnol (2001) 19:446–450.
   PubMed Web of Science ®Google Scholar
• •Exploitation of HIV-1 DNA flap to enhance lentiviral vector titre and transduction efficiency.
   Google Scholar
• ZENNOU V PETIT C, GUETARD D, NERHBASS U, MONTAGNIER L, CHARNEAU P: HIV-1 genome nuclear import is mediated by a central DNA flap. Cell (2000) 101:173–185.
   PubMed Web of Science ®Google Scholar
• CHARNEAU P, CLAVEL F: A single-stranded gap in human immunodeficiency virus unintegrated linear DNA defined by a central copy of the polypurine tract. J. Virol. (1991) 65:2415–2421.
   PubMedGoogle Scholar
• FOLLENZI A. AILLES LE, BAKOVIC S, GEUNA M, NALDINI L: Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. (2000) 25:217–222.
   PubMed Web of Science ®Google Scholar
• EMERY DW, YANNAKI E, TUBB J, STAMATOYANNOPOULOS G: A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc. Natl Acad. Sci. USA (2000) 97:9150–9155.
   PubMed Web of Science ®Google Scholar
• •Insulators allow long-term transgene expression from retroviral vectors.
   Google Scholar
• YANNAKI E, TUBB J, AKER M, STAMATOYANNOPOULOS G, EMERY DW: Topological constraints governing the use of the chicken H54 chromatin insulator in oncoretrovirus vectors. Mot Ther. (2002) 5:589–598.
   PubMed Web of Science ®Google Scholar
• AGARWAL M, AUSTIN TW, MOREL F, CHEN J, BOHNLEIN E, PLAVEC I: Scaffold attachment region-mediated enhancement of retroviral vector expression in primary T cells. J. Virol. (1998) 72:3720–3728.
   PubMed Web of Science ®Google Scholar
• •SARs are used in retroviral vectors to enhance transgene expression.
   Google Scholar
• AUTEN J, AGARWAL M, CHEN J, SUTTON R, PLAVEC I: Effect of scaffold attachment region on transgene expression in retrovirus vector-transduced primary T cells and macrophages. Hum. Gene Ther. (1999) 10:1389–1399.
   PubMed Web of Science ®Google Scholar
• DANG Q, AUTEN J, PLAVEC I: Human beta interferon scaffold attachment region inhibits de novo methylation and confers long-term, copy number-dependent expression to a retroviral vector. J. ViroL (2000) 74:2671–2678.
   PubMed Web of Science ®Google Scholar
• BESTOR TH, TYCKO B: Creation of genomic methylation patterns. Nat. Genet. (1996) 12:363–367.
   PubMed Web of Science ®Google Scholar
• HOEBEN RC, MIGCHIELSEN AA, VAN DER JAGT RC, VAN ORMONDT H, VAN DER EB AJ: Inactivation of the Moloney murine leukemia virus long terminal repeat in murine fibroblast cell lines is associated with methylation and dependent on its chromosomal position. J. ViroL (1991) 65:904–912.
   PubMed Web of Science ®Google Scholar
• JAENISCH R, JAHNER D, NOBIS P et al.: Chromosomal position and activation of retroviral genomes inserted into the germ line of mice. Cell (1981) 24:519–529.
   PubMed Web of Science ®Google Scholar
• BELL AC, FELSENFELD G: Stopped at the border: boundaries and insulators. Curr. Opin. Genet. Dev. (1999) 9:191–198.
   PubMed Web of Science ®Google Scholar
• LABRADOR M, GORGES VG: Setting the boundaries of chromatin domains and nuclear organization. Cell (2002) 111:151–154.
   PubMed Web of Science ®Google Scholar
• CHUNG JH, WHITELEY M, FELSENFELD G: A 59 element of the chicken beta-globin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila. Cell (1993) 74:505–514.
   PubMed Web of Science ®Google Scholar
• NAGAYAMA Y, NISHIHARA E, IITAKA M, NAMBA H, YAMASHITA S, NIWA M: Enhanced efficacy of transcriptionally targeted suicide gene/ prodrug therapy for thyroid carcinoma with the Cre-loxP system. Cancer Res. (1999) 59:3049–3052.
   PubMed Web of Science ®Google Scholar
• STEINWAERDER DS, LIEBER A: Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo. Gene Ther. (2000) 7:556–567.
   PubMed Web of Science ®Google Scholar
• VASSAUX G, HURST HC, LEMOINE NR: Insulation of a conditionally expressed transgene in an adenoviral vector. Gene Ther. (1999) 6:1192–1197.
   PubMed Web of Science ®Google Scholar
• TAN BT, WU L, BERK AJ: An adenovirus-Epstein-Barr virus hybrid vector that stably transforms cultured cells with high efficiency. J. ViroL (1999) 73:7582–7589.
   PubMed Web of Science ®Google Scholar
• DORIGO O, GIL JS, GALLAHER SD et aL: Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells. J. ViroL (2004) 78:6556–6566.
   PubMed Web of Science ®Google Scholar
• INOUE T, YAMAZA H, SAKAI Y et ell.: Position independent human B-globin gene expression mediated by a recombinant adeno-associated virus vector carrying the chicken B-globin insulator. J. Hum. Genet. (1999) 44:152–162.
   Google Scholar
• OGATA T, KOZUKA T, KANDA T: Identification of an insulator in AAVS1, a preferred region for integration of adeno-associated virus DNA. J. Virol. (2003) 77:9000–9007.
   PubMed Web of Science ®Google Scholar
• WADE-MARTINS R, SAEKI Y, CHIOCCA A: Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. Mot Ther. (2003) 7:604–612.
   PubMed Web of Science ®Google Scholar
• CHEN X, LI J, MATA M et al.: Herpes simplex virus type 1 ICP0 protein does not accumulate in the nucleus of primary neurons in culture. J. ViroL (2000) 74:10132–10141.
   PubMed Web of Science ®Google Scholar
• LACHMANN RH, BROWN C, EFSTATHIOU S: A murine RNA polymerase I promoter inserted into the herpes simplex virus type 1 genome is functional during lytic, but not latent, infection./ Gen. ViroL (1996) 77:2575–2582.
   PubMed Web of Science ®Google Scholar
• LACHMANN RH, EFSTATHIOU S: Utilization of the herpes simplex virus type-1 latency-associated regulatory region to drive stable reporter gene expression in the nervous system. J. ViroL (1997) 71:3197–3207.
   PubMed Web of Science ®Google Scholar
• BERTHOMME H, LOKENSGARD J, YANG L, MARGOLIS T, FELDMAN LT: Evidence for a bidirectional element located downstream from the herpes simplex virus type 1 latency-associated promoter that increases its activity during latency. J. Wrol. (2000) 74:3613–3622.
   Google Scholar
• PALMER JA, BRANSTON RH, LILLEY CE et aL: Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system. J. Wrol. (2000) 74:5604–5618.
   Google Scholar
• JIN BK, BELLONI M, CONTI B et aL: Prolonged in vivo gene expression driven by a tyrosine hydroxylase promoter in a defective herpes simplex virus amplicon vector. Hum. Gene Ther. (1996) 7:2015–2024.
   PubMed Web of Science ®Google Scholar
• KAPLITT MG, KWONG AD, KLEOPOULOS SP, MOBBS CV, RABKIN SD, PFAFF DW: Preproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector. Proc. Natl. Acad. Sci. USA (1994) 91:8979–8983.
   PubMed Web of Science ®Google Scholar
• POMERANZ LE, BLAHO JA: Assembly of infectious herpes simplex virus type 1 virions in the absence of full-length VP22. ViroL (2000) 74:10041–10054.
   Web of Science ®Google Scholar
• ELLIOTT G, O'HARE P: Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell (1997) 88:223-233. Characterisation of HSV-1 VP22 intercellular protein delivery activity.
   Google Scholar
• WYBRANIETZ WA, GROSS CD, PHELAN A et al.: Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene. Gene Ther. (2001) 8:1654–1664.
   PubMed Web of Science ®Google Scholar
• PHELAN A. ELLIOTT G, O& HARE P: Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat. BiotechnoL (1998) 16:440–443.
   PubMed Web of Science ®Google Scholar
• DE FILIPE P: Polycistronic viral vectors. Curr. Gene Ther. (2002) 2:355–378.
   PubMedGoogle Scholar
• ZHU Y, FEUER G, DAY SL, WRZESINSKI S, PLANELLES V: Multigene lentiviral vectors based on differential splicing and translational control. Mo/. Ther. (2001) 4:375–382.
   PubMed Web of Science ®Google Scholar
• MIZUGUCHI H, XU Z, ISHII-WATABE A, UCHIDA E, HAYAKAWA T: IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mo/. Ther. (2000) 1:376–382.
   PubMed Web of Science ®Google Scholar
• KOZAK M: Constrains on reinitiation of translation in mammals. Nud Acid Res. (2001) 29:5226–5232.
   PubMed Web of Science ®Google Scholar
• DONNELLY ML, HUGHES LE, LUKE G et al.: The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences. J. Gen. Virol. (2001) 82:1027–1041.
   PubMed Web of Science ®Google Scholar
• GERMANN UA, GOTTESMAN MM, PASTAN I: Expression of a multidrug resistance-adenosine deaminase fusion gene. J. Biol. Chem. (1989) 264:7418–7424.
   PubMed Web of Science ®Google Scholar
• ROGULSKI KR, KIM JH, KIM SH, FREYTAG SO: Glioma cells transduced with and Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radisensitivity. Hum. Gene Ther. (1997) 81:2573–2604.
   Google Scholar
• BAUM C, HEGEWISCH-BECKER S, ECKERT HG, STOCKING C, OSTERTAG W: Novel retroviral vectors for efficient expression of the multidrug-resistance (mdr-1) gene in early hemopoietic cells. J. Virol (1995) 69:7541–7547.
   PubMed Web of Science ®Google Scholar
• GREZ M, AKGUN E, HILBERG F, OSTERTAG W: Embryonic stem cell virus, a recombinant murine retrovirus with expression in embryonic stem cells. Proc. Natl Acad. Sci. USA (1990) 87:9202–9206.
   PubMed Web of Science ®Google Scholar
• SEN00 M, MATSUBARA Y, FUJII K et al.: Adenovirus-mediated in utero gene transfer in mice and guinea pigs: tissue distribution of recombinant adenovirus determined by quantitative TaqMan-polymerase chain reaction assay. MoL Genet. Metab. (2000) 69:269–276.
   Google Scholar
• NICKLIN SA, BAKER AH: Tropism-modified adenoviral and adeno-associated viral vectors for gene therapy. Cuff. Gene Ther. (2002) 2:273–293.
   PubMedGoogle Scholar
• CHAO H, LIU Y, RABINOWITZ J, LI C, SAMULSKI RJ, WALSH CE: Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mo/. Ther. (2000) 2:619–623.
   PubMed Web of Science ®Google Scholar
• CERIMELE F, CURRELI F, ELY S, FRIEDMAN-KIEN AE, CESARMAN E, FLORE O: Kaposi's sarcoma-associated herpesvirus can productively infect primary human keratinocytes and alter their growth properties. J. Virol. (2001) 75:2435–2443.
   PubMed Web of Science ®Google Scholar
• MESRI EA, CESARMAN E, ARVANITAKIS L et al.: Human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus is a new transmissible virus that infects B cells. J. Exp. Med. (1996) 183:2385–2390.
   PubMed Web of Science ®Google Scholar
• FLORE O, RAFII S, ELY S, O'LEARY JJ, HYJEK EM, CESARMAN E: Transformation of primary human endothelial cells by Kaposi's sarcomaassociated herpesvirus. Nature (1998) 394:588–592.
   PubMed Web of Science ®Google Scholar
• VAN CRAENENBROECK KV, VANHOENACKER K, HAEGEMAN G: Episomal vectors for gene expression in mammalian cells. Eur. j Biochem. (2000) 267:5665–5678.
   PubMedGoogle Scholar
• WANG J, VOS JM: Infectious Epstein-Barr virus vectors for episomal gene therapy. Methods Enzymol. (2002) 346:649–660.
   PubMed Web of Science ®Google Scholar
• WHITE RE, WADE-MARTINS R, JAMES MR: Infectious delivery of 120-kilobase genomic DNA by an Epstein-Barr virus amplicon vector. Mol. Ther. (2002) 5:427–435.
   PubMed Web of Science ®Google Scholar
• DELECLUSE HJ, HAMMERSCHMIDT W: The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy. J. Clin. Pathol (2000) 53:270–279.
   Web of Science ®Google Scholar
• MURCKE S, POLACK A, PAWLITA M et al.: Suitability of Epstein-Barr virus-based episomal vectors for expression of cytokine genes in human lymphoma cells. Gene Ther. (1997) 4:82–92.
   PubMed Web of Science ®Google Scholar
• HIRAI H, SATOH E, OSAWA M et al.: Use of EBV-based vector/HVJ-liposome complex vector for targeted gene therapy of EBV-associated neoplasms. Biochem. Biophys. Res. Commun. (1997) 241:112–118.
   PubMed Web of Science ®Google Scholar
• EHRENGRUBER MU, LUNDSTROM K, SCHWEITZER C, HEUSS C, SCHLESINGER S, GAEHWILER BH: Recombinant Semliki Forest virus and Sindbis virus efficiently infect neurons and hippocampal slice cultures. Proc. Natl. Acad. Sci. USA (1999) 96:7041–7046.
   PubMed Web of Science ®Google Scholar
• COOPER MJ, MIRON S: Efficient episomal expression vector for human transitional carcinoma cells. Hum. Gene Ther. (1993) 4:557–566.
   PubMed Web of Science ®Google Scholar
• STRAYER DS: Gene therapy using 5V40-derived vectors: what does the future hold? J. Cell. Physiol (1999) 181:375–384.
   Web of Science ®Google Scholar
• SCHNELL MJ, BUONOCORE L, KRETZSCHMAR E, JOHNSON E, ROSE JK: Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc. Nail. Acad. Sci. USA (1996) 93:11359–11365.
   PubMed Web of Science ®Google Scholar
• MILLER MA, LAVINE CL, KLAS SD, PFEFFER LM, WHITTA MA: Recombinant replication-restricted VSV as an expression vector for murine cytokines. Protein. Expr. Puri"' (2004) 33:92–103.
   PubMed Web of Science ®Google Scholar
• VERHOEYEN E, COSSET FL: Surface-engineering of lentiviral vectors. J. Gene Med. (2004) 6:S83–S94.
   PubMed Web of Science ®Google Scholar
• ANDERSON DB, LAQUERRE S, GOINS WF, COHEN JB, GLORIOSO JC: Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry. J. Virol (2000) 74:2481–2487.
   PubMed Web of Science ®Google Scholar
• TANG J, YANG T, GHOSH HP, GELLER Al: Helper virus-free HSV-1 vectors packaged both in the presence of VSV G protein and in the absence of HSV-1 glycoprotein B support gene transfer into neurons in the rat striatum. Neurovirol (2001) 7:548–555.
   PubMed Web of Science ®Google Scholar
• LEGRAND V, LEISSNER P, WINTER A. MEHTALI M, LUSKY M: Transductional targeting with recombinant adenovirus vectors. Curr. Gene Ther. (2002) 2:323–339.
   Google Scholar
• BUNING H, RIED MU, PERABO L et al.: Receptor targeting of adeno-associated virus vectors. Gene Ther. (2003) 10:1142–1151.
   PubMed Web of Science ®Google Scholar
• BURTON EA, BAI Q, GOINS WF, GLORIOSO JC: Targeting gene expression using HSV vectors. Adv. Drug. Deliv. Rev. (2001) 53:155–170.
   PubMed Web of Science ®Google Scholar
• LAQUERRE S, ANDERSON DB, STOLZ DB, GLORIOSO JC: Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. Virol. (1998) 72:9683–9697.
   Web of Science ®Google Scholar
• OHNO K, SAWAI K, IIJIMAY, LEVIN B, MERUELO D: Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A. Nat. Biotech. (1997) 15:763–767.
   PubMed Web of Science ®Google Scholar
• SAWAI K, MERUELO D: Cell-specific transfection of choriocarcinoma cells by using Sindbis virus hCG expressing chimeric vector. Biochem. Biophys. Res. Commun. (1998) 248:315–323.
   PubMed Web of Science ®Google Scholar
• HARUI A, SUZUKI S, KOCHANEK S, MITANI K: Frequency and stability of chromosomal integration of adenovirus vectors. J. Virol (1999) 73:6141–6146.
   PubMed Web of Science ®Google Scholar
• MITANI K, KUBO S: Adenovirus as an integrating vector. Curr. Gene Ther. (2002) 2:135–144.
   PubMedGoogle Scholar
• ZHENG C, BAUM BJ, IADAROLA MJ, O'CONNELL BC: Genomic integration and gene expression by a modified adenoviral vector. Nat. Biotechnol (2000) 18:176–180.
   PubMed Web of Science ®Google Scholar
• CAPLEN NJ, HIGGINBOTHAM JN, SCHEEL JR et al.: Adeno-retroviral chimeric viruses as in vivo transducing agents. Gene Ther. (1999) 6:454–459.
   PubMed Web of Science ®Google Scholar
• RECCHIA A, PARKS RJ, LAMARTINA S et al.: Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc. Nail. Acad. Sci. USA (1999) 96:2615–2620.
   PubMed Web of Science ®Google Scholar
• LIEBER A, STEIN WAERDER DS, CARLSON CA, KAY MA: Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes. J. Wrol. (1999) 73:9314–9324.
   Google Scholar
• FRAEFEL C, JACOBY DR, LAGE Get al.: Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors. Mol. Med. (1997) 3:813–825.
   Google Scholar
• JOHNSTON KM, JACOBY D, PECHAN PA et al.: HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum. Gene Ther. (1997) 8:359–370.
   PubMed Web of Science ®Google Scholar
• COSTANTINI LC, JACOBY DR, WANG S, FRAEFEL C, BREAKEFIELD XO, ISACSON O: Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors. Hum. Gene Ther. (1999) 10:2481–2494.
   PubMed Web of Science ®Google Scholar
• YANEZ RJ, PORTER AC: Therapeutic gene targeting. Gene Ther. (1998) 5:149–159.
   PubMed Web of Science ®Google Scholar
• SCHUBELER D, MAASS K, BODE J: Retargeting of retroviral integration sites for the predictable expression of transgenes and the analysis of cis-acting sequences. Biochemistry (1998) 37:11907–11914.
   PubMed Web of Science ®Google Scholar
• KOCH KS, AOKI T, WANG Yet al: Site-specific integration of targeted DNA into animal cell genomes. Gene (2000) 249:135–144.
   PubMed Web of Science ®Google Scholar
• WANG Q, TAYLOR MW: Correction of a deletion mutant by gene targeting with an adenovirus vector. Mol Cell. Biol. (1993) 13:918–927.
   PubMed Web of Science ®Google Scholar
• MILLER DG, RUTLEDGE EA, RUSSELL DW: Chromosomal effects of adeno-associated virus vector integration. Nat. Genet. (2002) 30:147–148.
   PubMed Web of Science ®Google Scholar
• HIRATA RK, RUSSELL DW: Design and packaging of adeno-associated virus gene targeting vectors. J. Wrol. (2000) 74:4612–4620.
   Google Scholar
• •Feasibility of gene targeting by AAV vectors.
   Google Scholar
• INOUE N, DONG R, HIRATA RK, RUSSELL DW: Introduction of single base substitutions at homologous chromosomal sequences by adeno-associated virus vectors. Md. The,: (2001) 3:526–530.
   PubMed Web of Science ®Google Scholar
• THYAGARAJAN B, OLIVARES EC, HOLLIS RP, GINSBURG DS, CALOS MP: Site-specific genomic integration in mammalian cells mediated by phage phiC31 integrase. Mol Cell. Biol. (2001) 21:3926–3934.
   PubMed Web of Science ®Google Scholar